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Abstract 
The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their 
classification is based on distinct clinicopathologic features. Although idiopathic inflammatory 
myopathies share some similarities, different subtypes may have variable responses to therapy, so it is 
very important to distinguish the correct subtype. 
There are few randomised, double blind placebo controlled studies to support the current treatment. 
High dose corticosteroids continue to be the first line therapy and other immunosupressive drugs are 
used in refractory cases, as well as steroid-sparing agents. 
Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, 
intravenous immunoglobulin and rituximab, following good outcomes reported in case studies. 
However, more randomised controlled trials are needed. 
This review considers the current and the potential future therapies for inflammatory myopathies. 
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Introduction 
The idiopathic inflammatory myopathies (IIM), including dermatomyositis (DM), polymyositis (PM), 
inclusion body myositis (IBM), and immune-mediated necrotizing myopathy (NM) [1-13] are 
heterogeneous conditions [1,3-6,13-17]. Their precise aetiology is unknown and they are 
characterized by muscle weakness and inflammation, combined with elevated muscle enzymes and 
characteristic changes on electromyography and muscle biopsy [1,5,17-19]. 
Some patients with inflammatory muscle disease may have a range of other autoimmune rheumatic 
conditions, including Systemic Lupus Erythematosus (SLE), Rheumatoid arthritis (RA), scleroderma. 
These patients are often referred to as overlap myositis and should be distinguished in context, for 
example, when selecting patients for clinical trials.  
These conditions are potentially treatable, but an early and correct diagnosis and institution of 
treatment are needed [10, 20, 21].  
There are few randomized studies to support the current treatment paradigm [2-4, 19, 20, 22, 23] 
which is still based primarily on clinical experience [2-4, 11, 16]. First-line therapy is invariably 
corticosteroids, [1, 3-7, 16, 17, 19-22, 24, 25] although there are no adequate randomized controlled 
trials to support this [3, 6, 9, 13, 17]. Other immunosupressives, notably azathioprine and 
methotrexate, are widely used as second-line agents in refractory cases or as steroid-sparing agents 
[1,3, 4, 6, 7, 9, 15, 16, 18-21, 25,26].  
DM, PM and NM usually have a good response to treatment with immunosuppressives [2, 10, 19, 20], 
but IBM is frequently resistant to these drugs, remaining a treatment challenge [2, 9, 10, 19, 27].  
The first key to successful treatment is a correct diagnosis [18]. When a patient with DM or PM is not 
responding to immunosuppressive treatment, physicians must not be afraid to ask themselves if the 
diagnosis is wrong [3, 6, 15, 16], before considering other therapeutic options [6, 15, 16]. 
A critical part of the evaluation of a patient with myositis is to distinguish between ‘disease activity’ 
which is a reversible process due to inflammatory changes that might respond to immunosuppressive 
treatment and ‘disease damage’ which is a persistent/permanent change in physiology, pathology or 
function, that will not respond to this treatment. Common diagnostic approaches include directed 
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physical examination, laboratory testing, MRI, repeated muscle biopsies and the use of IMACS tools 
[14].  
Other approaches such as intravenous immunoglobulin and rituximab have emerged as potential 
treatments for patients with myositis [9], but more randomized controlled trials are needed.  
 
CORTICOSTEROIDS 
High dose corticosteroids remain widely used [1, 3-7, 15, 16, 19-22, 24, 25]. Although widely 
prescribed as initial therapy of 1 mg/kg per day for a month, this dosage of prednisolone is probably 
unnecessary; our group, for example, uses 0.5mg/Kg/day. The dose is then gradually tapered within 
several weeks to the minimum maintenance dose to keep the disease controlled [6, 17-21]. The rate of 
taper is dependent on the patient’s clinical response [2,6].  
In severe cases, at the onset, methylprednisolone is used intravenously up to 1g per day, for 3-5 days 
[6,17, 18, 20].  
Response to corticosteroids should be evaluated by monitoring strength, serum muscle enzyme levels 
and repeat imaging [6, 18, 19]. It should be stressed that a simple reduction in muscle enzyme levels 
may be an insufficient guide to therapeutic response. 
Most patients with PM or DM have a (partial) response to corticosteroids [19]. However, in IBM 
prednisone is usually not effective, although some patients may improve temporarily [2 ,6, 11, 13, 
19].  
The great concern about the use of high doses steroids is its major side effects. These include 
osteoporosis, increased risk of infections, diabetes and hypertension. There is an increased risk of a 
fracture in patients on more than 5mg/day [2]. Steroids should be accompanied by 1000 mg calcium 
carbonate and 400-500 IU vitamin D per day [2, 17]. Pneumococcal and flu vaccine should be 
recommended [17, 28], ideally before starting therapy or during stable disease [28]. 
Another important side effect of glucocorticosteroids is the steroid-induced myopathy that can mimic 
a relapse [2,19]. 
A recent randomized controlled study compared oral dexamethasone pulse therapy (six monthly 
cycles of 40mg/day for four consecutive days) with oral daily prednisolone (70-90mg per day for one 
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month with slow taper for 44-52 weeks) and found no difference in efficacy. However, high dose 
dexamethasone causes substantially fewer side effects [17, 19, 21, 25], but has a shorter median time 
to relapse [25,29]. 
 
Immunosuppressive therapy 
Second-line immunosupressive agents should be added to corticosteroids in refractory cases or as 
steroid-sparing agents [1-4, 6, 7, 9, 15, 16, 18-22, 25, 26] or commenced at the same time in severe 
disease [2, 18]. There is no established time to begin steroids sparing agents, it is dependent on the 
response, side effects and inability to taper the steroid dose and the activity of the disease, especially 
if there is pulmonary/ pharyngeal involvement [19]. 
There are limited data about which agent should be used [18, 21, 25], but the choice includes 
azathioprine, methotrexate, intravenous immunoglobulin, mycophenolate mofetil and 
cyclophosphamide [18]. 
The commonly used immunosuppresive drugs may exert both a “steroid-sparing” effect (non evidence 
based) [10, 11, 13, 22], and provide a modest benefit themselves [10, 11, 13]. Monitoring of these 
potential powerful drugs is essential and includes regular (often every 4-8 weeks) blood tests, 
checking the full blood count, urea, electrolytes and liver function tests and, where available, serum 
drug levels (e.g. MMF) should also be undertaken [22]. 
Immunosuppressant drugs are generally ineffective in IBM [6]. 
In DM patients the use of topical agents such as tacrolimus, hydroxychloroquine and corticosteroids is 
recommended, as well as sunlight avoidance [6,19]. 
 
METHOTREXATE (MTX) 
MTX is given as a weekly maintenance dose of 7.5–25 mg [2, 17, 18, 20]. It can be administered 
orally or subcutaneously [18]. 
Common side effects include increase of the liver enzymes [2, 17, 18, 20] and myelosupression [17, 
18, 20], which should be monitored with laboratory tests. Therapy with MTX should be avoided in 
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patients with pulmonary involvement (interstitial lung disease) as MTX may on occasions cause 
pulmonary infiltrates [20]. 
MTX interferes in the folate metabolism, so folic acid supplement should be given to avoid toxicity 
[2, 17]. 
Response to methotrexate is likely to occur up to 3 months after starting therapy [17, 18]. 
Retrospective studies have shown MTX efficacy in DM and PM.[20]One randomized study 
comparing MTX versus placebo in IBM showed a significant decrease of the CK, but no change in 
disease progression [2,19]. 
 A trial comparing MTX with azathioprine in idiopathic inflammatory myopathy found equivalent 
efficacy, but MTX was better tolerated. Another trial compared cyclosporine with MTX in PM and 
DM and showed no statistically significant difference between the two [21]. 
Studies comparing methotrexate versus azathioprine, methotrexate versus cyclosporine and 
intramuscular methotrexate versus oral methotrexate plus azathioprine, showed no statistically 
difference in efficacy between the regimes [25]. 
 
AZATHIOPRINE (AZA) 
This drug is usually started at 50 mg/day for a week, and then increased weekly to 2-3 mg/kg/day [2, 
17, 18]. 
Bone marrow suppression is the major potential (although very uncommon) side effect of AZA [2, 
18], especially in patients with thiopurine-methyl-transferase deficiency. This enzyme activity should 
be measured, before starting the treatment [2, 17]. Increased liver enzymes may also occur [2,18]. 
During treatment with AZA, it is essential to check the blood count and liver enzymes, approximately 
every 6 weeks [2, 17, 18, 20]. If liver enzymes are markedly increased (2x above the normal range), 
AZA should be stopped until the enzymes normalize. If the leucocytes are below 250/μl or the 
absolute neutrophil count is below 1,000, it should be stopped [17]. 
Gastrointestinal toxicity (nausea, abdominal pain, vomiting and anorexia) may occur, but pulmonary 
toxicity is rare making AZA an appropriate choice for patients with pulmonary involvement [18]. 
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Angiotensin converting enzyme inhibitors should be avoided because of the risk of severe 
leucopoenia, and concomitant allopurinol requires a dose reduction of 25-33% [17]. 
And open-label follow-up of a prospective double-blind study and some retrospective studies have 
shown that AZA is effective in DM and PM [20]. 
Response to AZA often takes some months to occur. The peak is at 1-2 years [17]. This delay may 
explain why in a small controlled study comparing AZA (2mg/Kg/day) plus oral corticosteroids 
versus steroid alone, there was no improvement in CK levels or weakness with AZA at 3 months [17, 
19, 21]. However, after three years of “unblinded” follow-up, the AZA group had improved 
functional outcomes and lower doses of maintenance prednisolone [19, 21]. 
 In fact, combination therapy (AZA + prednisolone) seems to reduce the risk of relapse as well as 
improve long-term outcome. DM and PM patients who have pulmonary involvement (ILD), alone or 
as part of as anti-synthetase syndrome, may benefit from an initial combination therapy (with AZA 
and prednisolone) [20]. 
In a randomised double blind controlled trial comparing the use of methotrexate and steroids versus 
azathioprine and steroids, in the treatment of IIM, there was no difference between the two groups 
[17,30]. 
 
MYCOPHENOLATE MOFETIL (MMF) 
MMF is an anti-metabolite that blocks “de novo” purine synthesis and targets the production of 
activated B and T lymphocytes and fibroblasts [31]. 
MMF is administered orally, with a starting dosage of 500mg twice daily, which can be increased to 
2-3g/day [2, 18]. Side effects include kidney and liver toxicity, but these occur less frequently than 
with compared to MTX or AZT [2]. Gastrointestinal intolerance (diarrhoea) and leucopoenia are also 
important [2, 18]. 
A response to MMF should be seen within 2-3 months [18]. 
MMF is emerging as a promising drug [19, 21], especially when used in refractory IIM [3,4,19,32] 
(including refractory rash [3,4]) and in patients with ILD refractory to steroids [4,17, 31]. 
Small case series have shown objective muscle strength improvement in IBM treated with MMF [19]. 
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The use of MMF in severe cases of adult or juvenile myositis has been supported by uncontrolled 
trials [5]. 
 
CYCLOSPORIN A (CSA) 
This drug is usually administered in divided doses, orally, from 3 to 5 mg/Kg/day [18,21]. 
Its major side effects are liver [2,18] and kidney toxicity [2, 17, 18], as well as, bone marrow 
suppression [18] and hypertension [17,18]. 
A response should be seen within a few months [18]. 
CSA may be used to treat patients with PM or DM who have failed to respond adequately to 
corticosteroids [26]. It may also be useful in childhood DM [21]. 
In patients with pulmonary involvement refractory to steroids and with anti-Jo1 anti-synthetase 
syndrome, combination therapy with CSA has been shown to be safe, invariably, and as effective as 
second line agent [17]. 
 
CYCLOPHOSPHAMIDE (CyC) 
CyC is a third line drug [17] which is administered as monthly infusions pulses (1g/m2) [18, 19] or as 
daily therapy orally (1-2mg/kg/day) [33] and may be used in combination with corticosteroids [31]. 
CyC is less used due in part to its side effects [2,33], notably alopecia, haemorrhagic cystitis, sterility, 
teratogenicity, increased risk of infection and malignancy [18]. However, monthly intravenous CyC is 
associated with fewer adverse effects than daily oral administration [31]. 
It is reserved for IMM patients refractory to most other therapies [2, 20], especially in those with 
associated ILD [17, 19, 34, 35] and severe or refractory juvenile dermatomyositis [5]. 
Several case studies demonstrate the efficacy of treatment with CyC in PM/DM patients [31]. The 
combination therapy of CyC and corticosteroids was effective on pulmonary function in IIM patients 
with severe pulmonary involvement [33]. 
A study of 9 patients with PM and DM treated with intravenous pulse of CyC reported improvement 
and sustained response of the majority of the patients [36]. 
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Tacrolimus (TAC) 
Tacrolimus, a third line drug, [17] is administered orally, up to 2-3mg twice daily.  Common side 
effects are increased susceptibility to infection, alopecia, skin erythema, pruritus, gastrointestinal 
symptoms (constipation, diarrhoea and nausea), hypertension, renal and hematologic toxicity [18]. 
TAC acts as calcineurin inhibitor and suppresses T lymphocytes secreting cytokines, such as 
interleukin-2 [37]. 
Several case series and retrospective studies demonstrated TAC efficacy and tolerability in anti-
synthetase/ SRP antibody-positive patients [3,5 19] and also in others refractory patients,[17,19] 
including patients with ILD [4,17,31,34]. 
One prospective, open, non-randomized study of 9 patients with PM/DM has shown benefit in the 
majority of patients refractory to previous therapy [38]. 
In a retrospective study of 15 patients with PM/DM who had received oral TAC in addition to 
corticosteroids an improvement of muscle strength and CK levels was shown and also an accelerated 
tapering of corticosteroids [37]. 
A Japanese retrospective study of 49 patients with IIM and ILD has shown significantly longer event-
free and disease-free survival of the patients treated with TAC (25 patients) compared with those 
treated with other conventional agents. Outcome events were defined as severe adverse event, death 
or relapse of respiratory cause. Although this study has some limitations, it provides an incentive to 
the use of TAC in moderate/ severe IIM with pulmonary involvement [39,40, 41]. 
 
Intravenous Immunoglobulin (IVIG) 
IVIG has been used and reported to be effective in refractory/ severe disease.[1,2,6, 16, 19, 20, 26, 34, 
42] It is often “turned to” when side effects from immunosuppressives outweigh their clinical benefit 
[1, 15, 16]. It seems to have good outcome in associated ILD [1,20,34] and oesophageal involvement 
[1, 15, 16, 43]. 
Its use remains expensive, controversial [19] and needs to be individualized [20]. 
The initial dosage is 2-3g/Kg, as divided doses, often spread over 3 days and repeated every 4-8 
weeks [2,18]. 
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There are some important side effects such as increased risk of thrombosis [2, 17, 44] allergic 
reactions/anaphylaxis and fever [2, 17]. An immunoglobulin A deficiency should be excluded before 
starting the treatment, because these patients have an increased risk for allergic reactions [2, 17]. 
IVIG appears to be safe during pregnancy [1,2]. 
In controlled prospective studies, IVIG had improved dysphagia [ 45,46,47] , but had no impact in 
increasing of the limb strength [47-50]. 
In a case study, an IBM patient was reported to have had beneficial effects from low dose IVIG [1, 
27]. 
A retrospective study reported 8 patients with juvenile dermatomyositis, who were able to avoid 
steroids with combined therapy with IVIG and immunosuppressives including methotrexate. This is 
important to avoid prolonged exposure to steroids, especially in paediatric population [1, 51]. 
A study of 7 patients with refractory PM or DM used subcutaneous immunoglobulin, at home by 
programmable pump, reported good response to treatment. The 2g/kg/month dose of IVIG was 
equally fractioned in weekly subcutaneous doses. This method could be a safe, practical and also 
cheaper alternative, but more studies are needed [1, 17,52].  
If the patient is not responding to corticosteroids and IVIG, the diagnosis should be questioned and 
another muscle biopsy and an extended panel of myositis autoantibodies should be tested [6]. 
A hereditary myopathy must be excluded. If the diagnosis of IIM is confirmed, experimental 
treatment such as biologic agents should be considered [6]. 
 
Biologic therapy 
Advances in our understanding of the inflammatory pathways involved have suggested alternative 
therapies for patients with myositis inadequately responding to prednisone and other conventional 
immunosuppressive drugs. New biological agents in the form of monoclonal antibodies or fusion 
proteins selectively targeting B cells or T cells, cytokines and co-stimulatory or transduction 
molecules, are emerging as a promising option for refractory cases and may change the current 
outcome of myositis. 
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B-cell blockade 
RITUXIMAB (RTX) 
The chimeric monoclonal antibody RTX selectively depletes B-cells. It targets the CD20 antigen, 
present on the surface of immature memory B cells and B cells in the germinal centre, but not on pro-
B cells, early pre-B cells and plasma cells. It is approved for treating non-Hodgkin’s lymphoma, 
rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. It has also 
shown efficacy in treating other autoimmune diseases. Currently, RTX is the most promising 
biological therapy for refractory myositis. Several case series reported that RTX at 2 g (two infusions 
at a dose of 1000 mg, given two weeks apart) or 375 mg/m2 weekly for 4 consecutive weeks, can be 
of benefit in some disease subsets.  
In 2005, Levine et al [53] first described the use of RTX in six patients with DM resistant to 
conventional treatment. Improvement in muscle disease and skin lesions was observed in each patient, 
although four of them had disease relapse, coinciding with the return of B cells. Since then, there have 
been several other reports of beneficial effects of RTX in patients with myositis. In terms of PM, B-
cell depleting therapy has shown efficacy, even in refractory subsets such as those patients with anti-
signal recognition particle (SRP) antibody positive NM [54, 55]. RTX has also demonstrated efficacy 
in patients with DM with improvement of both muscle and skin disease [56, 57], although other 
studies reported limited response in patients with refractory skin involvement [58, 59]. Beneficial 
effects of RTX have been described in patients with juvenile DM [60, 61] and with anti-synthetase 
syndrome (ASS) [62, 63].  
Based on these promising results, the efficacy of RTX was tested in a randomized, double-blind, 
placebo-phase trial in adult and paediatric myositis. The ‘Rituximab In Myositis’ (RIM) trial [64] was 
conducted in 200 patients with refractory myositis treated for 44 weeks with different regimen of 
RTX (96 patients received 2 infusions at baseline whereas 104 patients received RTX 8 weeks later). 
Refractory disease was defined as failure to respond to steroids and at least one immunosuppressive 
agent. Although there was no significant difference in response time between the two treatment arms 
(primary endpoint), at week 44 an 83% success rate and a significant steroid-sparing effect were 
achieved in both groups. 
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Possible reasons for the failure of the RIM trial include the study design (notably the choice of a too 
short ‘placebo phase’ duration based on ethical considerations and the power calculation based on the 
premise that RTX had an early onset of action by 8 weeks), the use of a only partially validated core 
set of measures and the heterogeneity of myositis [65]. A post-hoc analysis of the subgroups in the 
RIM study showed that patients with the positivity of myositis-specific autoantibodies (mainly anti–
Jo-1 and anti–Mi-2 antibodies) seem more likely to have a clinical response to RTX [66]. Thus, there 
remains a belief that B cell depletion may be effective in autoantibody producing subjects, but there is 
little point in using RTX in the almost 20% of IIM patients with no definable myositis autoantibodies. 
The failure of RIM trial highlighted the need to develop new myositis response criteria which can 
predict outcomes more accurately and more careful planed studies are needed for further trials.   
 
T-cell blockade 
ABATACEPT 
Abatacept is a fusion protein containing the cytotoxic T lymphocyte antigen 4 (CTLA-4), a 
physiological antagonist of the co-stimulatory protein CD 28 on T cells, fused to the Fc region of a 
human immunoglobulin G1 (IgG1). Histopathological studies suggested that T cells may play a role 
in the pathogenesis of myositis due to the demonstration of infiltrating T lymphocytes and the 
expression of CD28 and CTLA-4 ligands in biopsies of patients with PM [67].  
There are three case reports showing beneficial effects of T cell blockade in myositis. Musuruana et 
al. [68] first introduced abatacept in a 51-year-old female patient with PM refractory to conventional 
treatment. At the last clinical evaluation, 3 years with abatacept, her myositis symptoms were 
attenuated (her muscle strength was normal in her neck extensors and upper limbs, although she 
required leg braces to walk); her CK serum levels were slightly altered and her aldolase was within 
the normal range.  
Later, an improvement in muscle and skin disease was reported in a patient with juvenile DM 
complicated by ulceration and calcinosis [69]. Recently, Kerola et al. [70] reported a case of a 46-
year-old female patient who developed a severe myositis overlap syndrome, including features of RA, 
peripheral vasculitis and ILD, refractory to different immunosuppressive and biologic drugs.  
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After a few infusions of abatacept, her serum CK was in the normal range. An improvement of her 
muscle strength was also observed, although her physical capacity was reduced due to disease 
damage. Based on these case reports, abatacept may be a potential option to be considered in 
refractory myositis. A phase II randomized clinical trial (ARTEMIS study) is underway to test this 
hypothesis. [71] 
 
Tumor necrosis factor blockade 
INFLIXIMAB 
Infliximab is a chimeric monoclonal antibody against the tumor necrosis factor α (TNFα). The 
rationale for using TNFα blockade in myositis is the up-regulation of TNFα and its receptor in muscle 
tissue of these patients and also the expression of this cytokine in the endothelium of subjects with 
DM [72]. Preliminary reports [73, 74] have shown an improvement in myositis after anti-TNF-α 
treatment. However, the results are conflicting. A pilot study conducted in 13 patients with refractory 
IIMs treated with infliximab reported no benefit [75]. MMT (manual muscle testing) did not improve 
in any patient. The lack of improvement in muscle strength was associated with persistent signs of 
inflammation in muscle biopsies or on MRI of thigh muscles. Similar results were reported in an 
open-label trial of infliximab combined with weekly methotrexate in drug-naive patients [76], which 
was terminated prematurely because of a difficulty in recruiting cases, due to disease progression and 
the occurrence of adverse events. Thus, at present, the use of infliximab in patients with treatment-
resistant myositis is not recommended.  
 
ADALIMUMAB 
Adalimumab is a fully human monoclonal antibody against TNF-α. In the available literature, we 
could only find one case report of the use of adalimumab in IIM patients. Da Silva et al [77] described 
a case of 49-year-old female patient with ASS which did not adequately respond to different 
immunosuppressive drugs. The authors reported that adalimumab was introduced to their patient 
because of a previous incorrect diagnosis of RA. Interestingly, adalimumab improved significantly 
her muscle strength and her arthritis, normalized her serum muscle enzymes completely and stopped 
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the progression of ASS-associated ILD. Further investigations are needed to confirm the efficacy of 
adalimumab in myositis. 
 
ETANERCEPT 
Etanercept is a fusion protein of TNF receptor bound to a constant portion of human IgG1.  
Sprott et al. [78] first reported the use of etanercept in a 50-year-old female patient with PM 
refractory to steroids and to immunosuppressive drugs. The patient showed a rapid improvement in 
her muscle strength and serum CK levels, and her daily prednisolone dose was slowly reduced and 
stopped. In 2006, Efthimiou et al. [79] published the results of six patients treated with etanercept, 
one with infliximab and one received sequential therapy with these drugs. Improvement of muscle 
strength and a decrease in serum levels of muscle enzymes was observed in six of the 8 patients. The 
main concern with this report is the combination of therapies with corticosteroids, immunosuppressive 
drugs and IVIG, which complicates the interpretation of which was the most helpful. This positive 
result was not confirmed by a 52-week pilot trial of etanercept compared to placebo [80] conducted in 
16 treatment-naïve patients with myositis. Although no statistically significant differences between 
treatment groups were found using the “International Myositis Assessment and Clinical Studies 
Group- definition of improvement” (IMACS - DOI) [81], etanercept demonstrated a significant 
steroid-sparing effect. In addition, at the end of the study etanercept-treated patients showed 
improvement of many IMACS criteria including the manual muscle testing, physician global and 
Health Assessment Questionnaire. The reasons why the study failed to achieve its primary efficacy 
endpoint may be the low number of patients and the high drop-out rate, supporting the need for larger 
controlled trials to substantiate the efficacy of TNF inhibitors in the treatment of myositis. 
Etanercept is not currently recommended for treatment of myositis. 
 
Interleukin-6 blockade 
TOCILIZUMAB 
The rationale for using Interleukin-6 (IL-6) blockade in patients with myositis is the over-expression 
of IL-6 in muscle tissue and in the sera of patients with myositis [82, 83]. 
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Our literature review identified only three case reports of the use of tocilizumab in myositis. In a first 
study, two patients with PM resistant to conventional treatment [84] have showed improvement in 
their clinical and laboratory findings after treatment with tocilizumab.  
Later, Kondo et al. reported a case of a 32-year-old Japanese woman with refractory overlap 
syndrome, manifesting with DM, scleroderma and RA [85].  After treatment with tocilizumab, she 
was asymptomatic and her serum CK was normal. These preliminary data support the need for further 
investigations and a randomized clinical trial is underway to test this hypothesis [86]. 
 
Interleukin-1 blockade 
ANAKINRA 
The production of Interleukin-1 (IL-1) by activated macrophages, endothelial cells and muscle fibres 
is increased in IIM and can mediate the muscle damage [87].  
A 12-month open-label study with anakinra, which inhibits activities of both IL-1α and IL-1β, 
reported an improvement in seven out of 15 patients with refractory myositis [88]. 
Interestingly, the inflammatory infiltrates were still present in repeat muscle biopsies and the IL-1 
expression was not correlated to clinical response. However, in the sera of these patients a shift of 
differentiation of T cells from T helper 17 to T helper 1 was reported, suggesting a systemic effect of 
anakinra. 
These preliminary results support the idea that the IL-1 blockade may have a role in subgroups of 
myositis, but more studies are needed. Gevokizumab, a potent monoclonal antibody binding strongly 
to IL-1 beta, is currently being studied in a global clinical trial [89]. 
 
Type 1 IFN blockade 
SIFALIMUMAB 
A rationale to use sifalimumab, an interferon (IFN) α-blocking agent, in myositis, is the frequent 
observation of the type I IFN inducible proteins and the IFN-regulated chemokines in muscle biopsies 
and sera of patients with DM and PM [90]. 
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In a first phase 1b clinical trial [91], sifalimumab showed a moderate suppression of cluster of genes 
induced by type I IFN, highly over-expressed in IIM patients compared to controls. Positive 
correlation between gene neutralization and improvement of muscle strength by MMT8 was also 
recorded. A follow-up study [92] reported a suppressive effect on T cell-related proteins and a 
reduction of T cells infiltration in the muscle of these patients by blocking type I IFN.  
 
Physiotherapy and Exercise 
Exercise was initially seen as potentially deleterious, but recently was shown to be safe and in some 
cases efficacious [8, 19, 32, 93-95]. Rehabilitation is an essential part of the treatment of myositis [2, 
8, 14, 94, 96]. Exercises should be prescribed individually and according to patients’ characteristics, 
notably disease activity, range of motion, manual muscle test or dynamometer measurements and 
cardiorespiratory capacity [94]. It is important to be aware that in severe cases the main role of 
physiotherapy is to maintain the adequate range of joints movement with passive exercises. Later, 
when the patient is getting better, active exercises can be used. 
Exercise with resistance and active exercise has demonstrated improvement in muscle endurance and 
strength as well as aerobic capacity and functional ability, in IIM including IBM patients [8, 94]. 
Controlled and randomized trials have indicated that increased aerobic capacity could mediate 
improvement in health and decrement in disease activity. Muscle atrophy caused by muscle 
inflammation and systemic corticosteroids treatment can also be prevented by exercise [8]. 
 
Expert commentary:  
Due to the lack of controlled trials to guide therapeutic decisions, the management of patients with 
myositis remains challenging. Unfortunately, progress has been slower than in other autoimmune 
diseases, because of the difficulty in conducting high quality trials, due to the rarity and heterogeneity 
of the disease. For these reasons, the choice of treatment in patients with IIM remains empirical. On 
the basis of clinical experience, most patients respond to an initial treatment with corticosteroids. In 
cases that fail to respond to treatment with steroids, immunosuppressive agents may provide a non 
evidence-based ‘steroid-sparing’ effect, but are often only partly effective. 
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In refractory cases, IVIG can be tried, based on a controlled study conducted in DM, followed by 
tacrolimus. RTX appears to be the most promising biologic agent. It showed beneficial effects in 
uncontrolled studies and in approximately 80% of patients in the RIM trial, although the primary and 
secondary endpoints were not met. IBM continues to be difficult to treat. Although a small number of 
patients with IBM may show an early partial response to steroids, they become resistant to most 
therapies and the disease slowly progresses. 
In spite of two negative trials, there remains a belief that IVIG may offer a short-term clinical benefit 
in some patients with IBM which is difficult to capture with the measures used [47, 50, 97]. 
Further better-designed controlled trials, using validated response criteria, are needed to achieve the 
best treatment for patients with IIM, that can arrest the disease progression. 
 
Five- year view:  
The availability of new agents approved to treat other systemic diseases potentially promise that they 
will be investigated also for patients with refractory myositis. A wide spectrum of cytokines, 
chemokines and growth factors have been reported to be up-regulated in the peripheral blood and in 
muscle tissues of patients with myositis compared with controls [98]. These molecules are different 
among the disease subtypes, reflecting their distinct clinical phenotypes. Several agents could be of 
interest for future studies of myositis treatment, including: alemtuzumab, which is a monoclonal 
antibody targeting the glycoprotein CD52 and was reported effective in PM [99]; drugs that target B-
cell growth factors, such as B-cell activating factor (BAFF) and a proliferation-inducing ligand 
(APRIL) [100]; anti-complement agents (eculizumab), for the treatment of DM which is caused by a 
complement mediated vasculopathy [101].  
Moreover, the future in IIM therapy may also include regenerative therapies such as gene therapy or 
the use of stem cells [18,19], and bone marrow transplantation [18]. Despite some early successful 
haematopoietic stem cell transplantation (HSCT) studies in refractory IIM [102-105], in 2012 a case 
of a refractory juvenile DM woman with recurrent deterioration one year after HSCT was reported. 
Severe complications after HSCT are common and more studies are needed to identify eligibility 
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criteria, outcome predictors and the adequate regimen [106]. Plasma exchange and leucapheresis have 
shown no benefit [7, 21, 25] and there are significant side effects [25]. 
In conclusion, targeting the precise pathogenetic molecules might have a potential in the future 
therapeutic management of IIM. The identification of responsive patients and specific therapies 
targeting the correct myositis subset can potentially prevent incorrect use of biologics. 
 
Key issues: 
» High dose corticosteroids remain first line therapy. 
» For severe cases, intravenous methylprednisolone (up to 1g/day) is used for 3-5 days. 
» Long term therapy with corticosteroids should be minimized. 
» Immunosupressive therapy should be considered if the disease is not controlled with minimal dose 
of corticosteroids alone or there is organ involvement. 
» Second line agents (MTX, AZT, CsA) are used in refractory/ severe disease or as steroid-sparing 
agents. 
» MMF and TAC are emerging as promising drugs. They are used especially in refractory IIM and in 
patients who experience side-effects from other treatments. 
» Due to its side effects, CyC is reserved for IIM patients refractory to most other therapies. Some 
case studies have shown efficacy in patients with pulmonary involvement, when combined with 
corticosteroids. 
» IVIG seems to have, apart from some partial improvement of muscle strength, good outcome in 
patients with pulmonary and oesophageal involvement. 
» Biologic agents are emerging as new therapeutic approaches, however more randomised and 
controlled studies are needed 
» Exercise is generally safe and efficacious. 
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